Audiologic Variability Among Patients Undergoing Cisplatin Treatment
SIG 6

INTRODUCTION
The article in this SIG 6 activity focuses on the audiologic variations seen among patients undergoing the same type of ototoxic drug treatment (cisplatin). Results show a large amount of audiologic outcome variability among the two patients examined, despite similar demographic factors, drug treatments, and types of cancer. Factors relating to ototoxic susceptibility are discussed, and the importance of otoxicity monitoring programs for early detection of audiologic change is highlighted.

LEARNING OUTCOMES
You will be able to:
- describe risk factors for cisplatin ototoxicity and the range of possible audiologic outcomes following cisplatin chemotherapy

CONTENTS
A Tale of Two Susceptibilities: Cisplatin Ototoxicity by Variability in Similar Patients by Amy Custer

PROGRAM HISTORY and IMPORTANT INFORMATION
Start date: November 10, 2022
End date: November 10, 2027

To earn continuing education credit, you must complete the learning assessment on or before November 10, 2027.

This course is offered for 0.05 ASHA CEUs (Intermediate level, Professional area).